Advertisement
The Lancet Rheumatology Home

About The Lancet Rheumatology

About the Journal


A voice for rheumatology specialists worldwide

The Lancet Rheumatology is an independent, monthly journal committed to publishing content relevant to rheumatology specialists worldwide, with a focus on studies that advance clinical practice, challenge the status quo, and advocate change in health policy.

We invite submissions of clinical research (with a focus on clinical trials), expert reviews, and provocative comment and opinion relating to the diagnosis and classification, management, and prevention of rheumatic diseases, including arthritic, musculoskeletal, and connective tissue diseases, as well as disorders of the immune system. The journal also publishes high-quality human translational studies that are supported by robust clinical data, with priority given to studies that identify potential new therapeutic targets, advance efforts toward precision medicine, or have the potential to directly inform future clinical trials. With a strong clinical focus, The Lancet Rheumatology provides an independent voice for the rheumatology community and advocates strongly for the improved lives of patients with rheumatic diseases around the globe.

Information for Authors

The Lancet Rheumatology publishes any original research contribution that illuminates or influences clinical practice, directly informs future clinical trials, or substantively improves our understanding of disease processes. The Lancet Rheumatology also publishes interesting and informative reviews on any topic within the spectrum of rheumatology. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. All papers should be written to be clearly understandable to the journal’s readers in a wide range of specialties and countries.

The journal publishes a range of article types that encompass all aspects of rheumatology: Comment, Correspondence, News, Article, Review, Health Policy, and Viewpoint.

All original research judged eligible for consideration by the journal’s editors will be peer-reviewed within 72 h and, if accepted, published within 8 weeks from submission. Most accepted Articles will be published online first before appearing in an issue of the journal. Wherever possible, figures and good quality photographs should be used to supplement and to enhance the text. We also welcome videos. All original research is subjected to the Lancet family of journals’ usual rigorous standards of external clinical and statistical peer review, and edited by experienced technical copy editors to the highest standards.

The Lancet journals are signatories of the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors (ICMJE Recommendations) and to the Committee on Publication Ethics (COPE) code of conduct for editors. We follow COPE's guidelines.

If your question is not addressed on these pages, please email the editorial staff at [email protected]

The Lancet journals are currently receiving unprecedented numbers of COVID-19 related submissions. If you receive a letter indicating your article is not suitable for publication, please consider it a decision that applies to all Lancet journals.

Manuscript submission

To submit your manuscript to The Lancet Rheumatology please visit https://www.editorialmanager.com/tlrheu

About the Editorial team

Heather Van Epps, Editor-in-chief
Heather obtained her PhD in immunology from the University of Massachusetts Medical Center, where she investigated human T cell responses to hantavirus infection. After her postdoctoral research in the laboratory of Eric Pamer at Memorial Sloan Kettering Cancer Center, USA, Heather embarked on an editorial career. She was an Editor at The Journal of Experimental Medicine for more than a decade before joining The Lancet Diabetes & Endocrinology as Deputy Editor in 2015. She later served as Deputy Editor for The Lancet Gastroenterology & Hepatology before becoming the inaugural Editor-in-Chief for The Lancet Rheumatology in 2019.

Anna Clark, Deputy Editor
Anna obtained her PhD in neuroscience from King’s College London where she examined neuroimmune components to persistent pain, with a focus on cytokine and protease communication between neurones and microglial cells in the spinal cord. She was a post-doctoral research fellow at King's College (London, UK) and the Medical University of Vienna (Vienna, Austria). Anna commenced her editorial career managing a portfolio of journals within the BMC-series as an Editor at BioMed Central. She then served as an Assistant Editor at BMJ Open, before joining The Lancet Rheumatology's launch team as Deputy Editor in 2019

Helen Brooks, Senior Editor
During her PhD in neuroscience, Helen researched the feasibility of a stem cell treatment for Batten disease, a childhood neurodegenerative disorder, at King’s College London (London, UK). She joined the Lancet family of journals in 2016 in the assistant editor team and did a secondment as the Journal Editor at Trends in Molecular Medicine (Cell Press) in 2018. She returned as a Senior Editor at The Lancet Neurology before joining The Lancet Rheumatology’s launch team in 2019.

Here is a list of the conferences we’ll be attending in 2020. Please email us if you’d like to arrange a time to meet: [email protected].

Date Conference City To be attended by
March
5–7, 2020
6th Systemic Sclerosis World Congress Prague Heather van Epps and Anna Clark
April
20-22, 2020
British Society for Rheumatology Annual Conference Glasgow Heather van Epps and Helen Brooks
June
3-6, 2020
EULAR European Congress of Rheumatology Frankfurt Heather van Epps, Anna Clark and Helen Brooks
November
6-11, 2020
The American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting Washington TBC

About the advisory board

The international advisory board consists of key opinion leaders and researchers from around the world who will lend their expertise to this journal. We are very grateful for their support and advice on editorial matters.

Ombudsman

Our ombudsman can: investigate delays in handling submitted manuscripts; discourtesy; failure to follow outlined procedures; failure to take reasonable account of representations to us by authors and readers; and challenges to the publishing ethics of the journal. If you have concerns about any of the above, please first contact an editor or the editorial inbox [email protected]; an editor will then respond to you (often, an editor can respond satisfactorily). If you remain dissatisfied with our response, please contact Malcolm Molyneux ([email protected])

Read more about the ombudsman and see our ombudsman's reports.

The Lancet Group’s Diversity Pledge and No All-Male Panel Policy

Read the Diversity Pledge and No All-Male Panel Policy

August 2020
Volume 2, Issue 8